HYPOTHESIS / AIMS OF STUDY: The 12 week Overactive Bladder Innovative Therapy (OrBIT) Trial was a randomized, multi-center, controlled study that demonstrated comparable effectiveness of percutaneous tibial nerve stimulation (PTNS) to extended-release tolterodine . The OrBIT 12 month study demonstrated the long term effectiveness of PTNS for the treatment of overactive bladder (OAB) with results showing that symptom improvements after 12-weekly PTNS treatments were sustained throughout 12 months of therapy . The objective of this study was to evaluate the treatment interval frequency necessary to maintain efficacy.
INTERPRETATION OF RESULTS: PTNS demonstrated sustained therapeutic efficacy over 12 months following initial success at 12 weeks. Subjects received as low as 1.2 treatments monthly to sustain symptom improvement throughout 12 months.
- Peters KM, MacDiarmid SA, Wooldridge LS, et al: Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 2009; 183: 1055.
- MacDiarmid SA, Peters KM, Shobeiri SA, Wooldridge LS, Rovner ES, at al: Long-Term Durability of Percutaneous Tibial Nerve Stimulation for the Treatment of Overactive Bladder. J Urol 2009; 183: 234.